{
    "clinical_study": {
        "@rank": "107780", 
        "arm_group": [
            {
                "arm_group_label": "Ultrapulse laser alone", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Ultrapulse laser plus Cellutome Harvesting system", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "This project aims to treat field cancerization ( pre-skin cancers) in a manner that will\n      reduce the future pre-skin cancers and non-melanoma skin cancers in patients with\n      significant photodamage.\n\n      This is 3 year prospective, randomized, controlled comparison of a single treatment with\n      carbon dioxide laser resurfacing vs. carbon dioxide resurfacing plus autologous epidermal\n      skin graft from a non sun exposed site vs. control.\n\n      Thirty subjects will receive treatment with each of the modalities.\n\n      The primary measures of efficacy are (a) count of the number of actinic keratosis and non\n      melanoma skin cancers, (b) blinded evaluation of severity from standard digital photographs\n      taken before and after the treatments, and (c) change in histology before and after\n      treatment. Safety measures include (a) pain, (b) scarring, (c) wound healing, (d) and\n      infection"
        }, 
        "brief_title": "Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study", 
        "condition": [
            "Extensive Photodamage", 
            "Actinic Keratosis", 
            "History of Numerous Skin Cancers"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Skin Neoplasms", 
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n          1. Subjects with ages between 18 and 85 years, male or female.\n\n          2. Subjects with at least 4 clinically diagnosed actinic keratoses (AKs) per treatment\n             site ( up to 200 sq cm), excluding the face and neck\n\n          3. Subjects with history of at least 1 non-melanoma skin cancer within the past year\n\n          4. Willingness to participate in the study\n\n          5. Informed consent agreement signed by the subject\n\n          6. Willingness to follow the treatment schedule and post treatment care requirements\n\n          7. Willingness to not use topical or systemic (oral) TREATMENT medications including\n             imiquimod, 5-Fluorouracil, photodynamic therapy, during the treatment period.\n\n          8. Has not had treatment for AKs in the treatment area for 4 weeks prior to enrollment\n\n        Exclusion criteria\n\n          1. Subjects with active skin cancer in the treatment area. Once the non-melanoma skin\n             cancer has been treated, the subject can be immediately enrolled.\n\n          2. Infection of the area to be treated\n\n          3. An open wound in the area to be treated\n\n          4. Presence of suntan in the area to be treated, or active tanning during the study\n\n          5. Subjects who have taken medication known to induce photosensitivity in the previous 3\n             months\n\n          6. The patient has any contraindication to use of the carbon dioxide laser, including\n             but not limited to, intake of isotretinoin in past 12 months; patients with reduced\n             adnexal structures (eg, scleroderma, irradiation or burns); patients with history of\n             vitiligo or psoriasis (risk of Koebnerization); history of keloids/hypertrophic\n             scarring.\n\n          7. Subject is unable to comply with treatment, home care or follow-up visits\n\n          8. Subject is pregnant or breast feeding\n\n          9. Prior use of topical retinoids, 5 fluorouracil, or imiquimod in treated areas within\n             one month of initial treatment\n\n         10. Prior skin treatment with laser or other devices in the treated area within two\n             months of initial treatment or during the course of the study;\n\n         11. Adverse reactions to compounds of any external agent (e.g., gels, lotions or\n             anesthetic creams) required for use in the study, if no alternative to the said agent\n             exists;\n\n         12. Concurrent inflammatory skin conditions, including, but not limited to, eczema,\n             contact dermatitis of any severity;\n\n         13. Active Herpes Simplex at the time of treatment;\n\n         14. Multiple dysplastic nevi in area to be treated;\n\n         15. Having a bleeding disorder or taking anticoagulation medications, including heavy use\n             of aspirin, in a manner which does not allow for a minimum 10 day washout period\n             prior to each treatment (as per the patient's physician discretion);\n\n         16. Significant concurrent illness, such as uncontrolled diabetes, (i.e., any disease\n             state that in the opinion of the Investigator would interfere with the anesthesia,\n             treatment, or healing process);\n\n         17. Mentally incompetent, prisoner or evidence of active substance or alcohol abuse;\n\n         18. Any condition which, in the Investigator's opinion, would make it unsafe (for the\n             subject or study personnel) to treat the subject as part of this research study;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02150863", 
            "org_study_id": "2014P000121"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Ultrapulse laser alone", 
                    "Ultrapulse laser plus Cellutome Harvesting system"
                ], 
                "intervention_name": "Ultrapulse Carbon Dioxide Laser", 
                "intervention_type": "Device", 
                "other_name": "Lumenis Ultrapulse"
            }, 
            {
                "arm_group_label": "Ultrapulse laser plus Cellutome Harvesting system", 
                "intervention_name": "Cellutome epidermal harvesting system", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "actinic keratosis", 
            "field cancerization", 
            "organ transplant patients"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "contact": {
                "email": "atremaine@partners.org", 
                "last_name": "Anne Marie Tremaine, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "investigator": {
                "last_name": "R. Rox Anderson, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study", 
        "overall_contact": {
            "email": "atremaine@partners.org", 
            "last_name": "Anne Marie Tremaine, MD", 
            "phone": "617-643-6211"
        }, 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital/ Wellman Center for Photomedicine", 
            "last_name": "Rox Anderson, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "This is done at every visit over the 3 year period", 
                "measure": "count of the number of actinic keratosis and non melanoma skin cancers in the treatment area", 
                "safety_issue": "No", 
                "time_frame": "The following visits: Baseline"
            }, 
            {
                "measure": "Change in histology: atypia and degree of p53 staining", 
                "safety_issue": "No", 
                "time_frame": "Visits: Baseline"
            }, 
            {
                "description": "This is done at every visit over the 3 year period", 
                "measure": "count of the number of actinic keratosis and non melanoma skin cancers in the treatment area", 
                "safety_issue": "No", 
                "time_frame": "The following visits: Week 4"
            }, 
            {
                "description": "This is done at every visit over the 3 year period", 
                "measure": "count of the number of actinic keratosis and non melanoma skin cancers in the treatment area", 
                "safety_issue": "No", 
                "time_frame": "The following visits:  Month 3"
            }, 
            {
                "description": "This is done at every visit over the 3 year period", 
                "measure": "count of the number of actinic keratosis and non melanoma skin cancers in the treatment area", 
                "safety_issue": "No", 
                "time_frame": "The following visits:  Month 6"
            }, 
            {
                "description": "This is done at every visit over the 3 year period", 
                "measure": "count of the number of actinic keratosis and non melanoma skin cancers in the treatment area", 
                "safety_issue": "No", 
                "time_frame": "The following visits:  1 year"
            }, 
            {
                "description": "This is done at every visit over the 3 year period", 
                "measure": "count of the number of actinic keratosis and non melanoma skin cancers in the treatment area", 
                "safety_issue": "No", 
                "time_frame": "The following visits:   1.5 year"
            }, 
            {
                "description": "This is done at every visit over the 3 year period", 
                "measure": "count of the number of actinic keratosis and non melanoma skin cancers in the treatment area", 
                "safety_issue": "No", 
                "time_frame": "The following visits:  2 year"
            }, 
            {
                "description": "This is done at every visit over the 3 year period", 
                "measure": "count of the number of actinic keratosis and non melanoma skin cancers in the treatment area", 
                "safety_issue": "No", 
                "time_frame": "The following visits: 2.5 year"
            }, 
            {
                "description": "This is done at every visit over the 3 year period", 
                "measure": "count of the number of actinic keratosis and non melanoma skin cancers in the treatment area", 
                "safety_issue": "No", 
                "time_frame": "The following visits:  3 year (End of Study)"
            }, 
            {
                "measure": "Change in histology: atypia and degree of p53 staining", 
                "safety_issue": "No", 
                "time_frame": "Visits: Month 3"
            }, 
            {
                "measure": "Change in histology: atypia and degree of p53 staining", 
                "safety_issue": "No", 
                "time_frame": "Visits: Year 3 (End of study)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02150863"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Richard Rox Anderson, MD", 
            "investigator_title": "Harvard Medical School Professor in dermatology, Director of the Wellman Center for Photomedicine; and adjunct Professor of Health Sciences and Technology at MIT", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Time to healing after treatment", 
                "safety_issue": "Yes", 
                "time_frame": "week 4"
            }, 
            {
                "measure": "Side effects reported by patient/ Investigator wound assessment", 
                "safety_issue": "Yes", 
                "time_frame": "Day 3"
            }, 
            {
                "measure": "Side effects reported by patient/ Investigator wound assessment", 
                "safety_issue": "Yes", 
                "time_frame": "Day 7"
            }, 
            {
                "measure": "Side effects reported by patient/ Investigator wound assessment", 
                "safety_issue": "Yes", 
                "time_frame": "Week 4"
            }
        ], 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}